Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Scinai Immunotherapeutics ( (SCNI) ) has issued an update.
On March 27, 2025, Scinai Immunotherapeutics announced a binding option agreement to acquire Pincell srl, an Italian biotech firm, and its novel antibody, PC111, aimed at treating severe dermatological conditions like Pemphigus and Stevens-Johnson Syndrome. This strategic move, coupled with a €12 million grant application under the EU’s FENG program, positions Scinai to advance PC111’s development, potentially offering a non-immunosuppressive treatment for these conditions, which lack effective alternatives. The acquisition and development of PC111 could significantly enhance Scinai’s market position in the biopharmaceutical industry, addressing a critical unmet medical need and potentially leading to accelerated regulatory approval.
More about Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. is a biopharmaceutical company that specializes in inflammation and immunology (I&I) biological products. It operates two business units: one focused on developing therapeutic products, particularly nanosized VHH antibodies targeting diseases with large unmet medical needs, and the other providing CDMO services, including drug development and clinical trial execution, to early-stage biotech companies.
YTD Price Performance: -1.02%
Average Trading Volume: 11,275
Technical Sentiment Signal: Buy
Current Market Cap: $2.9M
For detailed information about SCNI stock, go to TipRanks’ Stock Analysis page.